Drug Pipeline

Natalizumab Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
1
Recruiting
2
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-14 NCT05925049
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS)…		 date change Primary completion pushed: 2026-04-30 -> 2026-10-31
2026-05-14 NCT05925049
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS)…		 date change Completion pushed: 2026-04-30 -> 2026-10-31
Active Studies by Phase
Phase 2
1
Not specified
2
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT05418010 Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of… Multiple Sclerosis Recruiting
Not specified
NCT05925049 A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS)… Multiple Sclerosis Active, Not Recruiting
NCT05688436 A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants… Multiple Sclerosis Active, Not Recruiting
Sponsors Running Natalizumab Trials
Biogen (2) Queen Mary University of London (1)
Disease Areas
Multiple Sclerosis (3)
Get alerts when Natalizumab trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free